Reliance Life Sciences operates state-of-the-art facilities in life sciences domain.
The flagship facility is the Dhirubhai Ambani Life Sciences Centre (DALC) in Navi Mumbai spread over 20 acres. DALC is among the most diverse and integrated life sciences campuses in the world. Its diversity stems from the wide spectrum of areas of research and development undertaken and its integration comes from repository, laboratory research, pre-clinical research, clinical research and manufacturing facilities; all located in the same campus.
The Dhirubhai Ambani Life Sciences Centre houses research labs over 120,000 sq ft of space and has the following laboratories:
- Molecular Biology
- Animal Cell Culture
- Molecular Medicine
- Protein Chemistry
- Downstream Separation
- Protein Purification
- Synthetic Chemistry and Process Development
- Medicinal Chemistry
- Analytical Chemistry
- Radio Immunoassay
These labs are supported by on-campus utility systems for power, water, HVAC and gases.
Cord Blood Repository
Reliance Life Sciences has established South Asia's first, most advanced and completely automated stem cell enriched umbilical cord blood repository. This is the first cord blood repository in the world to be accorded a licence by an official regulatory authority, Food and Drug Administration (FDA), Government of India.
Reliance Life Sciences has established a state-of-the-art, barrier-maintained Animal Facility for breeding and experimentation on small animals to meet internal, as well as client needs.
The facility breeds and maintains animals in individual ventilated cages (IVC) and conforms to the guidelines outlined by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA).
It is the only facility in India designed to carry out experiments on immuno-compromised animals in a class 10,000 facility.
Plant 1 manufacturing facility of Reliance Life Sciences is located in Mumbai and is designed for manufacture of clinical lots and initial market introduction of plasma proteins and recombinant therapeutic proteins. This facility complies with cGMP guidelines, operates under licence from Indian FDA and is WHO-GMP certified.
Plant 2 manufacturing facility for commercial manufacture of recombinant proteins, as well as cell-based therapies, is located in Navi Mumbai. This facility has suites both for mammalian cell culture and microbial fermentation, and is EMEA approved. It incorporates state-of-the-art distributed control systems.
Plant 3 manufacturing facility for pharmaceutical APIs is
located in Navi Mumbai and is designed
to comply with EMEA and USFDA guidelines. It has received EU GMP certificate from German (Bavarian) authorities.
Plant 4 manufacturing facility for commercial scale manufacture of plasma proteins is located in Navi Mumbai and is designed to comply with EMEA and USFDA guidelines.
Plant 5 manufacturing facility for biopolymers and biochemicals for medical applications.
Plant 6 manufacturing facility for oncology formulations (oral solid dosages and injectibles) at Dhirubhai Ambani Life Sciences Center, Navi Mumbai received EU GMP certificate from UK MHRA.
Integral to Plant 1, 2 and 4 are separate fill-finish suites with high speed lines for vials and pre-filled syringes
Reliance Life Sciences has three cGMP cell processing suites in operation in Mumbai to meet clinical trials for cell-based therapies and initial market introduction. Eight more cGMP cell processing suites are operational at Plant 2 located at the Dhirubhai Ambani Life Sciences Centre.
Reliance Life Sciences has quality control laboratories located at the Dhirubhai Ambani Life Sciences Centre, Navi Mumbai and at the first cGMP facility in Mumbai. These laboratories are state-of-the-art facilities and include stability chambers and microbiology suites.
Reliance Life Sciences operates a three-clinic, 111 bed Phase I and Bioavailability/ Bioequivalence facility at the Dhirubhai Ambani Life Sciences Centre, Navi Mumbai and an 80-bed wireless telemetry equipped facility at Bangalore. These facilities are supported by in-house pathology and bioanalytical facilities.